Cargando…

Determination of Antimicrobial Resistance and the Impact of Imipenem + Cilastatin Synergy with Tetracycline in Pseudomonas aeruginosa Isolates from Sepsis

Pseudomonas aeruginosa is among the most ubiquitous bacteria in the natural world, exhibiting metabolic and physiological versatility, which makes it highly adaptable. Imipenem + cilastatin and tetracycline are antibiotic combinations commonly used to treat infections caused by P. aeruginosa, includ...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Sousa, Telma, Silva, Catarina, Alves, Olimpia, Costa, Eliana, Igrejas, Gilberto, Poeta, Patricia, Hébraud, Michel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673103/ https://www.ncbi.nlm.nih.gov/pubmed/38004699 http://dx.doi.org/10.3390/microorganisms11112687

Ejemplares similares

Study of Antimicrobial Resistance, Biofilm Formation, and Motility of Pseudomonas aeruginosa Derived from Urine Samples
por: de Sousa, Telma, et al.
Publicado: (2023)

The Impact of the Virulence of Pseudomonas aeruginosa Isolated from Dogs
por: de Sousa, Telma, et al.
Publicado: (2023)

Genomic and Metabolic Characteristics of the Pathogenicity in Pseudomonas aeruginosa
por: de Sousa, Telma, et al.
Publicado: (2021)

Increased antibiofilm and growth inhibitory effect of Imipenem/Cilastatin nanoliposomes against clinical Pseudomonas aeruginosa isolates
por: Milani, Faezeh, et al.
Publicado: (2023)

1309. Imipenem/Cilastatin/Relebactam (I/R) Alone and in Combination against Pseudomonas aeruginosa (PSA) in the In Vitro Pharmacodynamic Model
por: Chen, Iris H, et al.
Publicado: (2020)

1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Brown, Michelle, et al.
Publicado: (2018)

Imipenem-cilastatin-induced psychosis: a case report
por: Ninan, Jacob, et al.
Publicado: (2016)

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam
por: Girón, Rosa Mª, et al.
Publicado: (2022)

Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin
por: Agudelo, Maria, et al.
Publicado: (2019)

Putative Protein Biomarkers of Escherichia coli Antibiotic Multiresistance Identified by MALDI Mass Spectrometry
por: de Sousa, Telma, et al.
Publicado: (2020)

Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach
por: Ghazi, Islam M., et al.
Publicado: (2020)

Comparison of Efficacy of Cefoperazone/Sulbactam and Imipenem/Cilastatin for Treatment of Acinetobacter Bacteremia
por: Choi, Jun Yong, et al.
Publicado: (2006)

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections
por: Heo, Young-A.
Publicado: (2021)

Correction: Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach
por: Ghazi, Islam M., et al.
Publicado: (2020)

Metabolic alkalosis: A less appreciated side effect of Imipenem-cilastatin use
por: Panda, Pragyan Swagatika, et al.
Publicado: (2013)

Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
por: Kabbara, Wissam K, et al.
Publicado: (2015)

Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates
por: Shaaban, Mona I., et al.
Publicado: (2017)

Small bowel bleeding treated successfully with transcatheter arterial embolization with imipenem/cilastatin
por: Arima, Takahiro, et al.
Publicado: (2022)

Genomic Characterization of Imipenem- and Imipenem-Relebactam-Resistant Clinical Isolates of Pseudomonas aeruginosa
por: López-Pérez, Mario, et al.
Publicado: (2021)

Mechanisms of Heteroresistance and Resistance to Imipenem in Pseudomonas aeruginosa
por: Xu, Ye, et al.
Publicado: (2020)

Organic anion transporters also mediate the drug–drug interaction between imipenem and cilastatin
por: Zhu, Yanna, et al.
Publicado: (2020)

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
por: Rebold, Nicholas, et al.
Publicado: (2021)

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
por: Naik, Jaesh, et al.
Publicado: (2023)

1339. Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Kaye, Keith, et al.
Publicado: (2018)

Imipenem Resistant Pseudomonas aeruginosa: The fall of the final quarterback
por: Ameen, Nadya, et al.
Publicado: (2015)

New Synthesis of Gold‐ and Silver‐Based Nano‐Tetracycline Composites
por: Djafari, Jamila, et al.
Publicado: (2016)

New Synthesis of Gold‐ and Silver‐Based Nano‐Tetracycline Composites
por: Djafari, Jamila, et al.
Publicado: (2016)

Metabolic alkalosis: A less appreciated side-effect of imipenem cilastatin use-author's reply
por: Panda, P. S., et al.
Publicado: (2014)

Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections: A Meta-analysis
por: Sahra, Syeda, et al.
Publicado: (2021)

Imipenem-Resistant Pseudomonas aeruginosa: Risk Factors for Nosocomial Infections
por: Onguru, Pinar, et al.
Publicado: (2008)

Morphological and Bactericidal Effects of Amikacin, Meropenem and Imipenem on Pseudomonas aeruginosa
por: Moghoofei, Mohsen, et al.
Publicado: (2015)

Meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in ICU: an open randomised multicentre study
por: Verwaest on behalf of the Belgiun Multicentre study group, C
Publicado: (1997)

Imipenem-Cilastatin versus Sulbactam-Cefoperazone plus Amikacin in the Initial Treatment of Febrile Neutropenic Cancer Patients
por: ÖZYILKAN, Özgür, et al.
Publicado: (1999)

Bacteremia caused by Elizabethkingia meningoseptica in a mechanically ventilated patient successfully treated with imipenem-cilastatin and ciprofloxacin
por: Chen, Chang-Hua, et al.
Publicado: (2017)

Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs)
por: Huo, Xiaokui, et al.
Publicado: (2019)

Comments on the Published Meta-Analysis of Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections
por: Vaziri, Ali Zaman, et al.
Publicado: (2021)

Transcatheter arterial embolization using imipenem/cilastatin sodium and microspheres for traumatic pseudoaneurysm: A case report
por: Hirano, Takaki, et al.
Publicado: (2022)

Phenotypic Detection of Metallo-β-Lactamase in Imipenem-Resistant Pseudomonas aeruginosa
por: Khosravi, Yalda, et al.
Publicado: (2012)

Imipenem Resistance Mediated by bla(OXA-913) Gene in Pseudomonas aeruginosa
por: Moon, Dong-Chan, et al.
Publicado: (2021)

A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia
por: Kollef, Marin H, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1vvq9dh7oap1m55dbuqkup0drm